Search:
![](/images/loading2.gif)
You do not have permission to access this chart.
Please Sign Up or Login
News for Synlogic, Inc. (SYBX)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
3 days ago | Zacks Investment Research
3 days ago | PRNewsWire
a week ago | PRNewsWire
2 weeks ago | Zacks Investment Research
3 weeks ago | PRNewsWire
a month ago | Zacks Investment Research
a month ago | PRNewsWire
a month ago | PRNewsWire
2 months ago | PRNewsWire
2 months ago | PRNewsWire
About:
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Sector:
HealthcareIndustry:
BiotechnologyAddress:
Synlogic, Inc. 301 Binney Street Suite 402 Cambridge MA 02142 United StatesWebsite:
Home